Litcius/Paper detail

A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer

Anca Chelariu-Raicu, Alpa M. Nick, Renata R. Urban, Mary E. Gordinier, Carola Leuschner, Linda M. Bavisotto, Graziela Zibetti Dal Molin, John K. Whisnant, Robert L. Coleman

2020Gynecologic Oncology19 citationsDOI

Topics & Concepts

MedicinePaclitaxelClinical endpointAdverse effectInternal medicineOvarian cancerRandomized controlled trialRefractory (planetary science)GastroenterologyOncologyUrologyChemotherapyPharmacologyCancerAstrobiologyPhysicsHypothalamic control of reproductive hormonesOvarian cancer diagnosis and treatmentEstrogen and related hormone effects
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer | Litcius